Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 80
- Registration Number
- NCT05504252
- Locations
- 🇳🇴
St Olavs Hospital, Trondheim, Trondelag, Norway
🇳🇴Oslo University Hospital, Oslo, Viken, Norway
🇳🇴Akershus University Hospital, Lørenskog, Viken, Norway
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 702
- Registration Number
- NCT05498766
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 93
- Registration Number
- NCT05493332
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05482893
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT05479240
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 118
- Registration Number
- NCT05476796
- Locations
- 🇫🇷
CHU d'Estaing, Clermont-Ferrand, France
🇫🇷Institut Andrée Dutreix - Clinique de Flandre, Coudekerque-Branche, France
🇫🇷Clinique de l'Europe, Amiens, France
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Belgian Group of Digestive Oncology
- Target Recruit Count
- 134
- Registration Number
- NCT05472259
- Locations
- 🇧🇪
AZ Imelda, Bonheiden, Belgium
🇧🇪CHU Ambroise Paré, Mons, Belgium
🇧🇪Grand Hopital de Charleroi, Charleroi, Belgium
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT05435313
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
FOLFIRINOX + NIS793 in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Colin D. Weekes, M.D., PhD
- Target Recruit Count
- 4
- Registration Number
- NCT05417386
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT05412082
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.